annual meeting program - American Society of Clinical Oncology

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION
Genitourinary (Prostate) Cancer
Location: E Hall D2
CME credit: 3
Track(s): Genitourinary Cancer
Sunday, June 6, 2010
Dana E. Rathkopf, MD—Co-Chair
Memorial Sloan-Kettering Cancer Center
Evan Y. Yu, MD—Co-Chair
University of Washington
9:30 AM Intergroup randomized phase III study of androgen deprivation therapy
(ADT) � radiation therapy (RT) in locally advanced prostate cancer (CaP)
(NCIC-CTG, SWOG, MRC-UK, INT: T94–0110; NCT00002633). (Abstract
#CRA4504)
P. R. Warde, M. D. Mason, M. R. Sydes, M. K. Gospodarowicz, G. P. Swanson,
P. Kirkbride, E. Kostashuk, J. Hetherington, K. Ding, W. Parulekar, NCIC CTG
PR.3/MRC PRO7/SWOG JPR3 Investigators
9:45 AM Impact of radiotherapy (RT) combined with androgen deprivation (ADT)
versus ADT alone for local control in clinically locally advanced prostate
cancer. (Abstract #4505)
N. Mottet, M. Peneau, J. Mazeron, V. Molinie, P. Richaud
10:00 AM Surgical outcomes and implications for cure in active surveillance patients
who undergo delayed radical prostatectomy. (Abstract #4506)
B. J. Trock, Z. Feng, P. Landis, J. I. Epstein, B. Carter
Discussion
10:15 AM Anthony V. D’Amico, MD, PhD (Abstracts #4504–4506)
Dana-Farber Cancer Institute
Early Prostate Cancer: How Much Therapy Is Too Much?
10:30 PM A randomized phase III trial of denosumab versus zoledronic acid in patients
with bone metastases from castration-resistant prostate cancer. (Abstract
#LBA4507)
K. Fizazi, M. A. Carducci, M. R. Smith, R. Damião, J. E. Brown, L. Karsh,
P. Milecki, H. Wang, R. D. Dansey, C. D. Goessl
Discussion
10:45 AM Robert E. Coleman, MD, MBBS (Abstract #LBA4507)
Weston Park Hospital
The Role of RANKL in Castration-resistant Prostate Cancer
11:00 AM Cabazitaxel or mitoxantrone with prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC) previously treated with
docetaxel: Final results of a multinational phase III trial (TROPIC). (Abstract
#4508^)
J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen,
P. Matthews, A. O. Sartor, for the TROPIC Investigators
11:15 AM Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for
patients (Pts) with progressive castration-resistant prostate cancer (CRPC):
Results from the phase III ASCENT2 trial. (Abstract #4509)
H. I. Scher, K. N. Chi, R. De Wit, W. R. Berry, P. Albers, B. Henick, P. Venner,
A. Heidenreich, L. Chu, G. Heller
231
SUNDAY